Rochelle Lazarus Buys Shares of OGN $OGN

Key Points

  • Rochelle Lazarus bought 17,857 shares of Organon & Co. ($OGN) worth $239,998.
  • $OGN last traded around $13.44.

Rochelle Lazarus, insider at Organon & Co. ($OGN), bought 17,857 shares at an average price of $13.44, for a total transaction of $239,998. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.

Organon & Co. ($OGN) Stock

Last price$13.44
Market cap$3.53B
P/E ratio14.45
Forward P/E3.67
Beta1.54
52-week low$5.69
52-week high$13.49
50-day MA$11.88
200-day MA$9.04
Current ratio1.97
Quick ratio1.00
Debt-to-equity9.49

Organon & Co. Earnings

EPS (ttm)$0.93
Revenue (ttm)$6.16B
Revenue growth-3.5%
Net margin4.0%
Return on equity34.0%
Next earningsAug 4, 2026

Organon & Co. Dividend

Annual dividend$0.08
Dividend yield60.00%
Payout ratio8.6%
Ex-dividend dateMay 11, 2026

Analysts Set New Price Targets

Average target$11.25
High target$14.00
Low target$8.00
Analysts covering4

About Organon & Co.

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

ExchangeNYSE
SectorHealthcare
IndustryDrug Manufacturers - General
HeadquartersJersey City, NJ
CEOMr. Joseph T. Morrissey Jr.
Employees10,000

See Also

This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.